about
Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint ApproachTen things you should know about protein kinases: IUPHAR Review 14Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development.A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome.PTN signaling: Components and mechanistic insights in human ovarian cancer.Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.Therapeutic interventions to disrupt the protein synthetic machinery in melanomaPrimary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach.Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.Trametinib in the treatment of melanoma.Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Primary and Metastatic Melanoma With NTRK Fusions.DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.
P2860
Q24672143-E253C202-876D-454B-9702-61ADB5460B47Q26849417-4DB75D98-C05F-49FD-B252-B304958F7308Q30599549-218DBE94-26B8-4230-9697-E0916A602437Q34521260-DC464287-3954-4128-BDD2-97A096383087Q35033429-1C8E9327-0B9C-423E-9FD2-E395D1186CD3Q35685365-DAD06CD2-21D2-45DB-8E33-863E0301CDA4Q36311216-F1D40463-9D7A-47C3-9761-90CCA26A9CF4Q36473355-3CF8941A-2F27-4A12-9714-17A339C7457BQ37286919-9AF6C7EF-10A7-4551-88B3-A99DC5AAF4E0Q38110200-A2D16F97-8032-4D30-982D-7837A3524339Q38210286-0E2EEB3F-0AA2-4F71-9ABA-20885CE35421Q38392273-AAE025F0-7811-47DD-A48F-D18A015F54C9Q38913787-23997970-F86E-4309-A55F-59D4570E5C2DQ39107981-E7104168-2740-4D2A-9608-037DBD2086B9Q52570211-01F3F0BB-3B60-4C49-AB2A-3757CEE7CE1BQ52719529-F453FD8B-FBFC-406C-A484-C0F6D1FE444D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Trametinib (GSK1120212) in the treatment of melanoma.
@en
type
label
Trametinib (GSK1120212) in the treatment of melanoma.
@en
prefLabel
Trametinib (GSK1120212) in the treatment of melanoma.
@en
P2860
P1476
Trametinib (GSK1120212) in the treatment of melanoma.
@en
P2093
April K S Salama
Kevin B Kim
P2860
P304
P356
10.1517/14656566.2013.770475
P407
P577
2013-02-23T00:00:00Z